Allele-Specific PCR with Competitive Probe Blocking for Sensitive and Specific Detection of BRAF V600E in Thyroid Fine-Needle Aspiration Specimens
暂无分享,去创建一个
C. Wittwer | L. Rowe | J. Bentz | E. Jarboe | G. D. Smith | B. Chadwick | Luming Zhou | B. Collins | Barbara E. Chadwick | Carl T. Wittwer | G. Denice Smith | Elke A. Jarboe | Brian T. Collins
[1] C. Wittwer,et al. Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking, and melting analysis , 2011 .
[2] Y. Nikiforov. Molecular diagnostics of thyroid tumors. , 2011, Archives of pathology & laboratory medicine.
[3] Y. Nikiforov. Molecular analysis of thyroid tumors , 2011, Modern Pathology.
[4] P. Wolf,et al. COLD-HRM PCR versus conventional HRM PCR to detect the BRAF V600E mutation A real improvement? , 2011, The Journal of molecular diagnostics : JMD.
[5] P. Meltzer,et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. , 2010, The Journal of molecular diagnostics : JMD.
[6] G. Ellison,et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples , 2010, Journal of experimental & clinical cancer research : CR.
[7] F. Cianchi,et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. , 2010, The Journal of molecular diagnostics : JMD.
[8] M. Xing,et al. Prognostic utility of BRAF mutation in papillary thyroid cancer , 2010, Molecular and Cellular Endocrinology.
[9] H. Lee,et al. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. , 2010, American journal of clinical pathology.
[10] C. Wittwer,et al. Enrichment and detection of rare alleles by means of snapback primers and rapid-cycle PCR. , 2010, Clinical chemistry.
[11] D. Ball. Selectively targeting mutant BRAF in thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.
[12] M. Nikiforova,et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. , 2009, Surgery.
[13] Chunrong Yu,et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. , 2008, Cancer research.
[14] J. Bogers,et al. Cervical cytology biobanking: quality of DNA from archival cervical Pap-stained smears , 2008, Journal of Clinical Pathology.
[15] David Sidransky,et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. , 2007, The Journal of clinical endocrinology and metabolism.
[16] J. Bentz,et al. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis , 2007, Journal of Clinical Pathology.
[17] M. Ringel,et al. Targeting BRAF in thyroid cancer , 2007, British Journal of Cancer.
[18] Leslie R Rowe,et al. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis , 2007, Journal of Clinical Pathology.
[19] A. Lewiński,et al. BRAF mutations in papillary thyroid carcinoma. , 2006, Endocrine regulations.
[20] L. Rowe,et al. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules , 2006, CytoJournal.
[21] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[22] A. Thor,et al. The art and science of cytopathology: Richard M. DeMay, MD. Chicago IL, ASCP Press, 1996, 2 vol set, 1,289 pages, $285 , 1996 .